Splenic B‐Cell Lymphoma/Leukemia With TCL1 Gene Rearrangement
International Journal of Laboratory Hematology · 2026-06 · 48 (3) · 683-688
DOI: 10.1111/ijlh.70082 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Journal of Laboratory Hematology, online erschienen am 03.03.2026. Verfasst von Xin Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins, Gene Rearrangement, Lymphoma, B-Cell, Splenic Neoplasms. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
Background
Splenic B‐cell lymphoma/leukemia includes a group of indolent small B‐cell lymphomas/leukemias that share overlapping morphological and immunophenotypic features, making accurate diagnosis challenging. Specific gene rearrangements have not been commonly associated with splenic B‐cell lymphomas/leukemias, and the TCL1 gene rearrangement—characteristic of T‐cell prolymphocytic leukemia—has not been previously reported in B‐cell lymphomas/leukemias. Here, we report two unique cases of splenic B‐cell lymphoma/leukemia harboring an IGH::TCL1 rearrangement. Case Presentation Patient #1 was a 74‐year‐old man with a 25‐year history of low‐grade B‐cell leukemia involving the peripheral blood, spleen, and bone marrow. Patent #2 was a 54‐year‐old woman who recently presented with lymphocytosis and low‐level bone marrow involvement. Both patients were asymptomatic and incidentally found to have lymphocytosis. The neoplastic cells in both cases displayed polar villous cytoplasmic projections, were of B‐cell lineage, and were negative for CD5 and CD10. Notably, an IGH::TCL1 fusion was identified in both cases.
Conclusions
The identification of IGH::TCL1 fusion in these two cases of splenic B‐cell lymphoma/leukemia suggests that TCL1 gene rearrangements can occur in B‐cell lymphoma/leukemia and should not be considered exclusive to T‐cell prolymphocytic leukemia. Accurate diagnosis of splenic B‐cell lymphoma/leukemia with TCL1 rearrangement requires evaluation of morphologic and immunophenotypic features and genetic assessment of TCL1 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Pathology, Albany Medical College, Albany, New York, USA.
- Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Xin Wang
Zitieren
APA
Wang, X., Tang, G., Hu, Z., Medeiros, L. J., & Hu, S. (2026). Splenic B‐Cell Lymphoma/Leukemia With TCL1 Gene Rearrangement. International Journal of Laboratory Hematology, 48(3), 683-688. https://doi.org/10.1111/ijlh.70082
Vancouver
Wang X, Tang G, Hu Z, Medeiros LJ, Hu S. Splenic B‐Cell Lymphoma/Leukemia With TCL1 Gene Rearrangement. International Journal of Laboratory Hematology. 2026;48(3):683-688. doi:10.1111/ijlh.70082
BibTeX
@article{Wang2026,
author = {Wang, Xin and Tang, Guilin and Hu, Zhihong and Medeiros, L Jeffrey and Hu, Shimin},
title = {Splenic B‐Cell Lymphoma/Leukemia With TCL1 Gene Rearrangement},
journal = {International Journal of Laboratory Hematology},
year = {2026},
volume = {48},
number = {3},
pages = {683--688},
doi = {10.1111/ijlh.70082}
}
EUVIMED